391902-04-8

Upstream product

• 40274-29-1 1-(3-bromoprop-1-yn-1-yl)-4-fluorobenzene 
• 321575-01-3 tert-butyl 4-aminophenethyl{(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl}carbamate 

Downstream Products

• 391901-27-2 5-[(4-{2-[(2 S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-phenyl)-[3-{4-fluoro-phenyl)-prop-2-ynyl]-amino}-thiazolidine-2,4-dione 

Relevant academic research and scientific papers

Azolidines as beta-3 adrenergic receptor agonists

This invention provides compounds of Formula I having the structure wherein, A, X, Y, Z, W, R1, R2, R3, R4, R5, and R6 are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.